Citius Pharmaceuticals Inc (NAS:CTXR)
$ 0.66 -0.0242 (-3.54%) Market Cap: 119.24 Mil Enterprise Value: 107.06 Mil PE Ratio: 0 PB Ratio: 1.32 GF Score: 40/100

Citius Pharmaceuticals Inc at Dawson James Small Cap Growth Conference Transcript

Oct 12, 2022 / 07:30PM GMT
Release Date Price: $1.09 (-3.54%)
Unidentified Participant

Everybody, thanks for being here. Our next presenter, CEO of Citius Pharmaceuticals, ticker CTXR, Leonard Mazur. Thank you.

Leonard Mazur
Citius Pharmaceuticals, Inc. - CEO

Thanks for the introduction, and I want to thank everybody for taking the time out to be with us today, for those of you that are here in person as well as for everybody that's online. So just to give you a quick update here, we're going to be making some forward-looking statements. And as I always advise everybody, please consult either sec.gov for complete information on all our filings or go to our website: citiuspharma.com, well, where we have all our filings as well.

So with that, let me give you a quick overview of the company. So we're a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. So our portfolio is really segmented into the preclinical phase, as well as the clinical phase.

We have five assets, primarily in the preclinical phase with the Mino-Wrap, which something

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot